Zengpanpan Ye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zengpanpan Ye has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Xiaolin Ai
Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE, State Key Laboratory of Biotherapy, West China Second Hospital, Department of Neurosurgery, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, P. R. China
60 shared publications - Chao You
Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE, State Key Laboratory of Biotherapy, West China Second Hospital, Department of Neurosurgery, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, P. R. China
59 shared publications - Chaoxin Xiao
Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE, State Key Laboratory of Biotherapy, West China Second Hospital, Department of Neurosurgery, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, P. R. China
59 shared publications - Fan Fei
Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital 3
59 shared publications - Hao Huang
State Key Laboratory of Digital Medical Engineering, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China
59 shared publications - Huairui Yuan
University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania
59 shared publications
Latest Publications
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S3 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S3 describes that inhibiting nuclear translocation of NR4A2 hampers immunosuppressive functions and promotes antigen presentation capacities of microglia.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S3 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S3 describes that inhibiting nuclear translocation of NR4A2 hampers immunosuppressive functions and promotes antigen presentation capacities of microglia.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Table S2 describes information of key research agents, data deposition and software versions.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Table S2 describes information of key research agents, data deposition and software versions.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S2 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S2 describes that oxidative stress in microglia promotes the immunosuppressive functions of microglia.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S2 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S2 describes that oxidative stress in microglia promotes the immunosuppressive functions of microglia.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S6 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S6 describes that inhibition of NR4A2 or SQLE improves the therapeutic efficacy of immune checkpoint blockade.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S6 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S6 describes that inhibition of NR4A2 or SQLE improves the therapeutic efficacy of immune checkpoint blockade.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S5 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S5 describes that genetic knockout of Nr4a2 in microglia reverses immunosuppressive state.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S5 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S5 describes that genetic knockout of Nr4a2 in microglia reverses immunosuppressive state.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Table S3 describes primer information for qPCR analysis.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Table S3 describes primer information for qPCR analysis.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S4 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S4 describes that NR4A2-knockdown affects lipid metabolism and promotes antigen presentation of microglia.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S4 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S4 describes that NR4A2-knockdown affects lipid metabolism and promotes antigen presentation of microglia.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S1 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S1 describes elevated oxidative stress challenge in the microglia of glioma.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S1 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S1 describes elevated oxidative stress challenge in the microglia of glioma.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Table S1 describes glioma patients and tissue samples information for evaluating the relationship of oxidative stress in microglia and prognosis
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Table S1 describes glioma patients and tissue samples information for evaluating the relationship of oxidative stress in microglia and prognosis
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S7 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S7 describes that oxidative stress in microglia as an independent predictor for clinical outcome in glioma patients.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S7 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S7 describes that oxidative stress in microglia as an independent predictor for clinical outcome in glioma patients.